procedures, the device, or the administered drug (for example, hypotonia, somnolence, headache, nausea, urinary retention, or dizziness) 22 and the effects due to overdose or withdrawal.
In this study we analyzed complications related to surgical procedures and device problems, dividing them into major complications, defined as events that required a surgical intervention to resolve, and minor complications, defined as events that did not require a surgical procedure. We also noted infections, catheter-related problems, and cerebrospinal fluid (CSF) leaks. Our findings were focused on technical problems and CSF leaks directly related to the catheter.
In the present article we describe complications that occurred in 508 patients treated with ITB from 1998 until August 2014 before and after the introduction, in September 2011, of the new Ascenda intrathecal catheter (Medtronic Inc.), which has an innovative design compared with the silicone catheter.
Methods

Clinical approach
This work was performed at the pediatric orthopedic department at the "V. Buzzi" Children's Hospital in Milan, Italy. Our center takes a multidisciplinary approach to patient management and is specialized in the treatment and correction of orthopedic deformities due to neurological disorders of childhood and development. Procedures for implantation of an ITB system are usually performed by the same surgeon (F.M.).
Patient selection for ITB is currently performed according to the treatment guidelines provided by Dan et al., 6 while patient management and clinical procedures have been standardized over the years, taking into consideration the available best practices. Patients selected for ITB, or their parents, sign an informed consent form and their data are registered in a database.
Collected data included product-related and clinical information assessed at baseline and at follow-up visits by means of validated scales specifically selected according to diagnosis, patient age, Gross Motor Function Classification System (GMFCS) level, 17 and functional and clinical conditions. The GMFCS is a 5-level classification system that describes gross motor function in patients with CP on the basis of self-initiated movement.
surgical Procedure
The procedure was performed under fluoroscopy with the patient under general anesthesia. Via a paramedian oblique approach, the needle was inserted into the intrathecal space at an angle of approximately 30°, until the dura was penetrated. After removing the stylet, we injected 5 ml of normal saline intrathecally to decrease the incidence of post-dural puncture headache, 8 and the catheter was guided along the vertebral canal up to the appropriate level for the intended therapeutic aim. We then prepared the anchor site by making an incision at the needle site to expose the fascia. For implants with the Ascenda catheter, we located the anchor dispenser and released the anchor. The silicone catheter did not have an anchor dispenser.
After preparing the subfascial pocket, the pump segment of the catheter was tunneled and then connected to the spinal segment; subsequently, the catheter was connected to the pump and internalized.
The procedure for pump placement was modified in March 2003. Previously, the pump had been placed in a subcutaneous abdominal pocket, whereas later it was placed more deeply into the abdomen, under the external oblique muscle and the abdominal rectus. This different procedure was intended to minimize infection risk and pump decubitus that might occur. 16 In addition, to minimize infection, we also introduced a preoperative prophylaxis protocol including antibiotic administration for 48 hours and antibacterial washing with iodopovidone the evening before the procedure and before entering the operating room.
All patients were implanted with a SynchroMed EL or SynchroMed II programmable pump (Medtronic Inc.). The intrathecal catheters used were the InDura intrathecal catheter (model 8709SC, Medtronic Inc.) and, since September 2011, the new Ascenda intrathecal catheter (model 8780, Medtronic Inc.; https://professional. medtronic.com/pt/neuro/itb/prod/ascenda-intrathecalcatheter/index.htm).
The Ascenda intrathecal catheter body provides increased resistance to kinking, cuts, occlusions, and leaks when exposed to tensile and compressive forces. The increase in the overall strength and durability of the catheter is achieved by an inner lumen of silicone tubing covered by a thermoplastic polyethylene terephthalate (PET) braid and a polyurethane outer jacket. The Ascenda catheter features a unique 4-layer design to prevent collapse, kinking, and occlusion. A PET braid serves as a flexible endoskeleton within the catheter to distribute force. The inner silicone tubing used in the Ascenda catheter is made of the same material used in the InDura catheter (model 8709SC). Reducing the outer diameter without minimizing the strength and long-term performance of the catheter is achieved by pairing polyurethane 80A and 55D. Table 1 shows the materials and benefits of the Ascenda catheter.
Significant Complications
We defined major complications as events that required surgical intervention and minor complications as events that resolved spontaneously and did not require a surgical procedure. The 3 most common complications of ITB are infection, CSF leakage, and catheter-related problems.
1
Infection is the most serious complication, commonly due to Staphylococcus aureus, and usually requires system explantation and the administration of intravenous antibiotics.
A CSF leak is defined as a CSF leak from the thecal sac. It appears as subcutaneous swelling posteriorly beneath the lumbar incision, anteriorly over and around the pump, or both and usually develops within the first 2 weeks after surgery. Usually patients with CSF leaks are symptom free but have visible and palpable signs, such as swelling. Cerebrospinal fluid leakage can be solved in 3 ways: with bed rest and abdominal pressure dressing; with bed rest, abdominal pressure dressing, and acetazolamide infusion; or with blood patch if the nonsurgical solutions do not work. In cases of an open wound, it is advisable to use glue or sutures.
Device problems are those related to the catheter, which could leak, break, tear, kink, or disconnect, resulting in an underdosage or abrupt cessation of ITB. 7, 15, 20, 22 These problems can be observed through radiography or contrast injection. The pump itself could flip over in the pocket with the anterior surface faced posteriorly. In this case the pump could be surgically secured to the fascia.
As regards infections and CSF leakage, these events usually occur in the 2 weeks after surgery, while catheterrelated problems occur later. 16 
Data Collection and analysis
We examined data related to major and minor complications occurring in our population. Our analysis included data on patients affected by events as well as the total number and details of the events that occurred. In assessing major complications, we compared the 2 groups of patients who had received implants with either the silicone or the Ascenda catheter. Continuous data were presented as the mean ± standard deviation. Categorical variables were presented as the absolute and relative frequency, and differences between groups were evaluated with the Fisher exact test and chi-square test. A p value < 0.005 was considered statistically significant.
results overall Characteristics
The study population was composed of 508 consecutive patients followed up for a mean of 8.4 ± 4.6 years (minimum 0.41 years, maximum 16.22 years). There were 312 males and 196 females, with a mean age at implantation of 13.41 ± 5.8 years, and the majority (451 patients) were affected by CP (88.8%). The SynchroMed EL system was implanted in 197 patients, while the SynchroMed II system was implanted in the remainder. In the considered period, 154 patients needed pump replacement due to battery depletion, and the pump was replaced twice in 12 of them. From the beginning of the study period in September 1998 until September 2011, 416 children were implanted with the InDura catheter (model 8709SC); thereafter, 92 patients were implanted with the Ascenda catheter. Table 2 lists the demographics for the 2 patient groups.
Overall Complications
In the silicone group, 120 patients had a major complication (29%), and in the Ascenda group, 1 patient (1.1%) had a complication (p < 0.001, Fisher exact test; Table  3 ). Table 4 shows the details for each group, and Table  5 shows the summary of major and minor complications.
infections
In the non-Ascenda group, infections were present in 43 patients for a total of 45 events, while no infectious events occurred in the Ascenda group. The consistent use of the subfascial technique and the preoperative prophylaxis protocol since March 2003 probably contributed to a constant decrease in infections. In the Ascenda group, which was subsequent to the silicone group, all patients were implanted according to this procedure. Note that the infection is not related to the implantation of the new catheter but only to the surgical technique; thus, the data related to infection have been inserted in the analysis only as clinical data.
Cerebrospinal Fluid leakage
As regards CSF leakage as a major complication, we found 23 patients (5.5%) in the non-Ascenda group who were affected. The leak was usually treated with 1 or more venous patches, but in 3 cases the system was explanted. In the Ascenda group, only 1 patient (1.1%) had a CSF leak, which led to system explantation (p < 0.005). In addition, CSF leaks clearing spontaneously without any intervention were not considered a major complication. This occurred in 15 other patients (3.6%) in the nonAscenda group and in 10 patients (10.9%) in the Ascenda group (p < 0.005; Table 6 ).
Catheter Problems
In the non-Ascenda group, we found 82 catheter-related events, such as occlusion, dislodgment, disconnection, or breakage, in 75 patients (18%). These events resulted in catheter replacement in 69 patients (92%), while in the other 6 cases (8%) the catheter was removed with the pump. Seventeen of the 69 patients replaced the catheter with an Ascenda, and no complications were observed. In the Ascenda group, no problems were found.
In the data we collected, the revision/replacement or removal time and not the onset time of the complication was considered. The number of events that occurred on an annual basis for the entire study interval is shown in Table 7 .
Discussion
Intrathecal baclofen therapy is an effective treatment for managing spasticity of different origins; however, complications related to the device or the administered drug are known to occur and must be managed. 16 Among all complications, most are catheter related. This can be confirmed thanks to analyses performed by the company Medtronic, which annually publishes results on their own product performance (http://professional.medtronic.com/ performance).
In this study we analyzed 508 consecutive pediatric patients who had undergone ITB system implantation in our department for the treatment of spasticity and/or dystonia and compared patients implanted with the standard silicone catheter with those implanted with the new Ascenda catheter. This is the first study to analyze and compare the Ascenda with the traditional intrathecal silicone catheter. The Ascenda catheter features a unique 4-layer design to reduce catheter problems such as collapse, kinking, and occlusions. There are multiple tests performed on the Ascenda catheter system by Medtronic as part of their design verification process. Design verification testing has been submitted for regulatory review as part of the regulatory approval process and is proprietary to Medtronic. Common catheter-related complications or failure modes include kinking and/or occlusion of the catheter, fractures and breaks of the catheter, and dislodgment of the catheter from the intrathecal space. A majority of the tests measure performance against these catheter complications to confirm Ascenda catheter robustness and reliability. To date, only one test has been published, and it assesses Ascenda catheter performance against the dislodgment failure mode in particular. 12 Adverse events related to the catheter were the most frequent, and their frequency was similar to rates reported by other authors.
Our previous work 16 revealed that the majority of events occur during the first 12 months after implantation, while the number of patients with a complication related to the catheter decreases in the following years. This may be explained by the fact that a certain time interval is required before catheter stabilization in the intrathecal space. With this assumption, which indicates that the critical period is represented by the first 12 months, the 2 groups are com- parable despite the different mean follow-up periods. Further investigation is necessary to expand and confirm our results. The large number of treated patients, the long followup period, and the standardization of clinical and technical procedures according to available guidelines and best practices allowed a reliable description of the complications that occurred.
As regards CSF leakage, we observed its decrease as a major complication, defined as a complication that requires surgical intervention to be resolved, versus its increase as a minor complication. The relatively high rate of this major complication in the non-Ascenda group may be explained by the larger size of the Tuohy needle used to insert the traditional silicone catheters. Tuohy needles used for the silicone catheter are 15 gauge, whereas the Tuohy needles used to insert the Ascenda catheter are smaller, that is, 16 gauge.
As regards technical catheter-related problems, the significant reduction in complications could be explained by the innovative design of the Ascenda catheter, with its new 4-layer structure designed to reduce kinks, breaks, leaks, and occlusions. A break is generally caused by fatigue due to forces placed on the catheter during anatomical motions throughout the life of the implanted catheter. The Ascenda has greater overall strength and improved resistance to cuts, breaks, or fractures as a result of the stronger properties in the catheter's polyurethane layer.
Dislodgment, as observed in the clinical setting, is a result of the relative motion between the fascia and skin acting on the catheter and anchor. Possible modes of catheter dislodgment are migration of the catheter relative to the fascia, distal to the anchor, and migration of the catheter relative to the anchor due to forces applied during anatomical movement. Current catheter models use a subcutaneous anchor to stabilize the catheter and prevent dislodgment. After the catheter has been inserted into the intrathecal space, the anchor is sutured where the catheter exits the fascia. Despite this prevention technique, dislodgment can still occur. The Ascenda catheter allows easier insertion into the fascia for secure placement given its unique anchor dispenser and eliminates catheter migration through the anchor, which is securely placed by the new anchor dispenser.
Catheter occlusion occurs when the catheter lumen is blocked. Different actions can cause an occlusion during the implant assembly process, such as sutureless pump connector misalignment, pump port puncture to catheter tubing leading to occlusion within the pump connector, or catheter connector pin puncture. The Ascenda catheter prevents partial or full occlusion of the catheter's inner lumen through the use of a layer of PET braid. When exposed to cyclic fatigue forces, compressive loading forces, and rotational forces, the inner lumen of the catheter remains open. Instead of concentrating applied loads, the PET braid distributes the load.
Conclusions
The most delicate component in an implantable drug infusion system has always been the catheter; a dislodgment, kink, tear, or break in the catheter could interrupt intrathecal therapy and increase the patient management burden. We are the first to compare the performance of the new Ascenda catheter, introduced in 2011, with the traditional silicone catheter for intrathecal drug infusion. In our analysis, we observed that the Ascenda catheter can reduce major catheter-related complications and CSF leakage after ITB pump implantation. Further investigation is necessary to expand and confirm our results.
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